Sleep Aids Market to be driven by the Stress Syndrome
Stress backed by changing lifestyles is resulting in loads of chronic conditions. Majority of them are related to inadequate sleep. With consumers ignoring it initially, further complications happen, which again prove to be problematic due to delayed diagnosis. Sleep aids are being made available in the form of OTC drugs/devices. This factor is bound to bolster the sleep aids market in the years to come. Persistence Market Research has thrown light on the same through its latest market study mentioned below.
How does the Sleep Aids market categorize itself?
The sleep aids market, by product, states drugs (insomnia treatment drugs (Doxepin Hydrochloride, Eszopiclone, Ramelteon, Triazolam, and Zaleplon), Quazepam, Narcolepsy Treatment Drugs, Modafinil, Sodium Oxybate, Armodafinil, and likewise), devices (CPAP devices, BiPAP devices, APAP devices), and others (mattresses & pillows, chin straps, and nasal devices and mouthpieces). Indication-wise, it’s insomnia, sleep deprivation, narcolepsy, sleep apnea, and likewise. By distribution channel, it’s hospital pharmacies, retail pharmacies, e-Commerce, drug stores, and likewise. Persistence Market Research has listed down these categorizations in its latest market study entitled “Sleep Aids Market”.
The Regions say…
North America holds the largest market share due to the US being home to majority of market players. Research states that close to 50-70 Mn adults all across the US suffer from sleep disorder. Moreover, insomnia has turned out to be the common disorder. Europe stands second with Germany being at the top. This could be attributed to growing incidences of sleep disorders due to excessive smoking and alcoholism, growing aging population, and likewise. Coming to the Asia-Pacific, China and India are holding the baton due to increasing incidences of insomnia and sedentary lifestyles (which result in irregular sleep patterns). LATAM and MEA are new entrants as of now, but expected to catch up over the period of time. Persistence Market Research has highlighted these details with the probable call to action in its latest market study entitled “Sleep Aids market”.
Get To Know More – https://www.persistencemarketresearch.com/samples/2832
The Movement called “Competition”
Persistence market Research has profiled the key players in sleep aids market as Cadwell Industries, Inc., Compumedics Ltd. (D & DJ Burton Holdings Pty Ltd.), DeVilbiss Healthcare LLC (Medical Depot, Inc.), SleepMed (BioSerenity), Sanofi, Pfizer, Inc., Merck & Co., Inc., Natus Medical Incorporated, Koninklijke Philips N.V., and GlaxoSmithKline plc. Coming to developments, Persistence Market Research has enlisted them in the reverse chronological order. For instance – Sandland Sleep, in April 2021, did launch a holistic series of sleep aids that have been scientifically proven to aid the customers in naturally improving their sleep. Also, Eisai Co., Ltd., in December 2019, did mention about the US FDA approving a novel drug application for the orexin receptor antagonist prepared in-house, which was known as DAYVIGOTM (lemborexant). Besides, Philips, in September 2019, did come up with NightBalance. It’s a new-fangled sleep position therapy device to treat people affected with obstructive sleep apnea (OSA). The positional therapy offered by the device lets patients alter their sleeping positions, thereby preventing apnea.
The sleep aids market ought to reach a new “high” in the healthcare vertical – Persistence Market Research